CHMP adopts positive opinion of haemophilia B treatment, Alprolix
Swedish Orphan Biovitrum (Sobi) and Biogen have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending that marketing authorisation be granted for Alprolix (rFIXFc) for the treatment of haemophilia B.
Click on this link for more information.
